大分割放疗对比常规分割放疗治疗鼻咽癌初诊远处转移:多中心、前瞻性、随机、II期试验
该多中心前瞻性随机II期试验纳入35例初诊远处转移鼻咽癌患者,随机接受大分割联合化疗(HFRT组17例,60 Gy/25次)或常规分割联合化疗(CFRT组18例,69.96 Gy/33次)。主要终点无进展生存(PFS)2年率HFRT组33.3% vs CFRT组30.0%(分层HR 1.09,95%CI 0.45-2.65,P=0.843),总生存(OS)2年率66.7% vs 62.5%(分层HR 0.88,95%CI 0.31-2.51,P=0.806)。所有患者出现急性1-2级毒性,无3-4级急性毒性;HFRT组2例听力损失(1级和3级各1例),CFRT组3例1级听力损失;HFRT组1例黏膜坏死。
要点
- 初诊远处转移鼻咽癌患者中,HFRT组与CFRT组的2年PFS和OS均无显著差异。
- 所有患者出现急性1-2级毒性,无急性3-4级毒性;HFRT组发生1例3级听力损失和1例黏膜坏死。
- 作者认为适当降低总剂量但提高分次剂量以改善严重晚期毒性与局部控制的平衡具有显著临床意义。
核心结论
- 作者认为,通过适当降低总剂量但提高分次剂量来改善严重晚期毒性与局部控制之间的平衡,对这些患者具有显著临床意义。
研究设计与样本
- 多中心、前瞻性、随机、II期试验,2014年5月至2020年6月纳入35例初诊远处转移鼻咽癌患者,随机分配至HFRT联合化疗组(n=17)或CFRT联合化疗组(n=18);HFRT组给予60 Gy/25次,CFRT组给予69.96 Gy/33次,均每周5次;主要终点为PFS,次要终点包括OS、LRRFS、DMFS及急性和晚期毒性。
主要发现
- 2年PFS为HFRT组33.3% vs CFRT组30.0%(分层HR 1.09,95%CI 0.45-2.65,P=0.843)。
- 2年OS为HFRT组66.7% vs CFRT组62.5%(分层HR 0.88,95%CI 0.31-2.51,P=0.806)。
- 所有患者出现急性1级或2级皮肤毒性、口腔黏膜炎、吞咽困难、口干,但无急性3级或4级毒性。
- 所有患者出现1级晚期口干;HFRT组2例听力损失(1级和3级各1例),CFRT组3例1级听力损失;HFRT组1例黏膜坏死。
关键数值与推荐
- HFRT组放疗剂量为60 Gy/25次,CFRT组为69.96 Gy/33次,两组均每周5次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To investigate the safety and efficacy of hypofractionated plus chemotherapy in patients with initially distant metastatic nasopharyngeal carcinoma (mNPC). MATERIALS AND METHODS: Between May 2014 and June 2020, 35 patients initially diagnosed with mNPC were enrolled on prospective trial. The enrolled patients were assigned randomly to receive either hypofractionated plus chemotherapy (HFRT) or conventionally fractionated radiotherapy plus chemotherapy (CFRT). 60 Gy over 25 fractions was administered to the HFRT group (n = 17) and 69.96 Gy over 33 fractions was administered to the CFRT group (n = 18), both groups five times each week.Progression free survival (PFS) comprised the primary endpoint. Overall survival (OS), locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), and acute and late toxicity comprised the secondary endpoints. RESULTS: Twenty-eight patients (seven were excluded) were enrolled. The 2-year PFS was 33.3% (HFRT group) versus 30.0% (CFRT group) (stratified hazard ratio (HR):1.09; 95% confidence interval (CI): 0.45-2.65, P = 0.843). The 2-year OS was 66.7% (HFRT group) versus with 62.5% (CFRT group) (stratified HR, 0.88; 95% CI; 0.31-2.51, P = 0.806). All patients experienced acute grade 1 or 2, skin toxicity, oral mucositis, difficulty swallowing, xerostomia, but no acute grade 3 or 4 toxicities. All patients had grade 1 late xerostomia. Two patients experienced hearing loss in the HFRT group (one grade 1 and one grade 3), and three patients experienced grade 1 hearing loss in the CFRT group. One patient developed mucosal necrosis in the HFRT group. CONCLUSION: Improving the balance between severe late toxicities and local control by appropriately reducing the total dose but increasing the fractionated dose has marked clinical significance for those patients.
引用
- Liu J, Zhang B, Su Y, et al. Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial. Radiother Oncol. 2023. PMID: 37480994. doi:10.1016/j.radonc.2023.109815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。